Sickle Cell Anemia in Children
15
2
2
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.7%
1 terminated out of 15 trials
88.9%
+2.4% vs benchmark
27%
4 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease
Hypoxic Red Blood Cells in Sickle Cell Anemia
Effect of Aquatic Exercises on Muscle Strength and Quality of Life in Children With Sickle Cell Anemia
The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia
Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)
Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
PINPOINT: Gaming Technology for SCD Pain
Low Systemic/High Local Exercise Load in Peds SCD
The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia
Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients
Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD